Nasopharyngitis
Showing 1 - 25 of 9,841
Acute Nasopharyngitis Trial in Vienna (2-Deoxyglucose, Placebo)
Recruiting
- Acute Nasopharyngitis
- 2-Deoxyglucose
- Placebo
-
Vienna, AustriaMedical University of Vienna
Mar 29, 2022
Cold Symptom Trial in Ferrara (DefensePlus, Placebo)
Recruiting
- Cold Symptom
- DefensePlus
- Placebo
-
Ferrara, ItalyAzienda Ospedaliero Universitaria di Ferrara
Jan 13, 2023
Acute Rhinitis, Nasal Obstruction, Rhinosinusitis Trial (Measurement of peak nasal flow.)
Not yet recruiting
- Acute Rhinitis
- +4 more
- Measurement of peak nasal flow.
- (no location specified)
Aug 8, 2022
Covid19, Nasopharyngitis, Anosmia Trial in Ivano-Frankivsk (BNO 1030, Standard care)
Completed
- Covid19
- +6 more
- BNO 1030
- Standard care
-
Ivano-Frankivsk, UkraineIvano-Frankivsk National Medical University
Mar 12, 2021
Tonsillopharyngitis, Rhinopharyngitis Trial in Timisoara (Standard of care + PediaFlù®, Standard of care)
Completed
- Tonsillopharyngitis
- Rhinopharyngitis
- Standard of care + PediaFlù®
- Standard of care
-
Timişoara, Timis, Romania
- +2 more
Sep 7, 2021
Meniere's Disease Trial in San Diego (OTO-104)
Terminated
- Meniere's Disease
-
San Diego, CaliforniaMany sites in Europe. Refer to the contact info listed below.
Dec 28, 2022
Caused by Anti-CGRP mAbs in Migraine Patients Treated With
Recruiting
- Migraine Disorders
- Diagnostic radiology
-
Lugano, Ticino, SwitzerlandChiara ZECCA
Sep 6, 2023
Healthy Volunteers Trial in Darmstadt, Munich (Restylane Lidocaine, No-treatment control)
Completed
- Healthy Volunteers
- Restylane Lidocaine
- No-treatment control
-
Darmstadt, Germany
- +1 more
Aug 24, 2022
Tenofovir Disoproxil Fumarate and Entcavir in Treatment of
Recruiting
- Chronic Hepatitis b Patients
- Tenofovir Disoproxil Fumarate and Entcavir
-
Sohag, EgyptSohag University hospitals
May 22, 2023
Foot Dermatoses Trial in Reykjavik (Loceryl NL + Cosmetic varnish, Loceryl NL 12 weeks, Loceryl NL 15 months)
Completed
- Foot Dermatoses
- Loceryl NL + Cosmetic varnish
- +2 more
-
Reykjavik, IcelandPrincipal Investigator
Jan 17, 2023
Acne Scars Trial in Boom (Restylane Vital Lidocaine)
Completed
- Acne Scars
- Restylane Vital Lidocaine
-
Boom, BelgiumSkin and Laser Center
Aug 24, 2022
Gepant treAtments: EffectIveNess and tolERability (GAINER)
Not yet recruiting
- Migraine
- +3 more
- Rimegepant 75 MG Disintegrating Oral Tablet
-
Florence, Italy
- +1 more
Jun 15, 2023
Sjögren-Larsson Syndrome Trial in Omaha, Hershey, Fairfax (Active topical NS2 1% dermatologic cream, Vehicle 0.0% NS2
Completed
- Sjögren-Larsson Syndrome
- Active topical NS2 1% dermatologic cream
- Vehicle placebo 0.0% NS2 dermatologic cream
-
Omaha, Nebraska
- +2 more
Nov 16, 2022
Velopharyngeal Insufficiency Trial in Assiut (adenotonsillectomy, adenoidectomy, tonsillectomy)
Recruiting
- Velopharyngeal Insufficiency
- adenotonsillectomy
- +2 more
-
Assiut, EgyptENT Department
Apr 7, 2023
Dry Eye Disease Trial in United States (CyclASol topical ocular, eye drops, Vehicle topical ocular, eye drops)
Completed
- Dry Eye Disease
- CyclASol topical ocular, eye drops
- Vehicle topical ocular, eye drops
-
Newport Beach, California
- +8 more
Dec 21, 2022
Atopic Dermatitis Trial in Australia, New Zealand, United States (BTX 1204, Vehicle)
MDD, Treatment Resistant Depression, Depression Trial in United States (AXS-05)
Completed
- Major Depressive Disorder
- +2 more
- AXS-05 (dextromethorphan and bupropion) oral tablets
-
Phoenix, Arizona
- +50 more
Sep 16, 2022
Severe Asthma Trial in Japan (Biological: Experimental: Tezepelumab)
Completed
- Severe Asthma
- Biological: Experimental: Tezepelumab
-
Chuo-ku, Japan
- +4 more
May 9, 2022
Dragon Study: To Assess Growth and Immune-related Outcomes
Not yet recruiting
- Healthy Nutrition
- No intervention
- (no location specified)
Jul 26, 2022
Arthritis, Juvenile Trial in Worldwide (Golimumab, Methotrexate)
Active, not recruiting
- Arthritis, Juvenile
-
San Diego, California
- +37 more
Jan 17, 2023
Rhinitis, Allergic, Perennial Trial (mometasone furoate)
Completed
- Rhinitis, Allergic, Perennial
- mometasone furoate
- (no location specified)
Feb 7, 2022